Search
  • Search
Ireland: Tenders/Irish Blood Transfusion Service/Fibrinogen concentrate used for congenital afibrinogenaemia and dysfibrinogenaemia

  1. Supplier selection

    Jan 1, 2024 12:00 AMJanuary 1, 2024 12:00 AM

  2. Contract signed

    Jan 2, 2024 12:00 AMJanuary 2, 2024 12:00 AM

  3. Result notice published

    Mar 28, 2024 9:43 AMMarch 28, 2024 9:43 AM

Brief

Fibrinogen concentrate used for congenital afibrinogenaemia and dysfibrinogenaemia

Awarded

The competition has ended and a winner has been selected.

Deadline
Mar 27, 2024Expired
Procedure
OpenSingle stage
Agreement
Buying goods

Brief

Human fibrinogen concentrate is used for congenital afibrinogenaemia and dysfibrinogenaemia states for treatment of bleeding complications. It is also used in acquired hypofibrinogenemia conditions such as massive haemorrhage, acquired coagulopathy, liver disease with bleeding and in obstetric haemorrhage. The product should be licensed for these clinical indications and approved by the HPRA. Fibrinogen, in presence of thrombin, activates FVIII and calcium, which is necessary to convert fibrinogen into stable three-dimensional fibrin coagula. The IBTS is responsible for the distribution of fibrinogen to users nationwide. IBTS must therefore have a sufficient stock and a stable supply of fibrinogen concentrates to meet patient needs.

Medisinsk engroshandel

Result

TED
  • Octapharma AG
    Winner
  • Number of bids
    2
  • Contract value
    €0

Custom Assessment Criteria

  • Get answers to your bid/no-bid criteria

    Set them up once and Cobrief answers them in every tender

Will you bid?

The agent sets up the bid and writes the first draft. Free for 14 days.

Award Criteria

  • Description

    Quality

    Source

    No source found in the documents. Check the weight against the tender documents.

Previous winners

  • Who are you up against?

    The suppliers who have won similar contracts at Irish Blood Transfusion Service

From the notice

  • Human fibrinogen concentrate is used for congenital afibrinogenaemia and dysfibrinogenaemia states for treatment of bleeding complications. It is also used in acquired hypofibrinogenemia conditions such as massive haemorrhage, acquired coagulopathy, liver disease with bleeding and in obstetric haemorrhage. The product should be licensed for these clinical indications and approved by the HPRA. Fibrinogen, in presence of thrombin, activates FVIII and calcium, which is necessary to convert fibrinogen into stable three-dimensional fibrin coagula. The IBTS is responsible for the distribution of fibrinogen to users nationwide. IBTS must therefore have a sufficient stock and a stable supply of fibrinogen concentrates to meet patient needs.

  • Contact

    brian.boland@ibts.ie
  • Type
    Result
  • Main code
    Medicinal products for the blood, blood-forming organs and the cardiovascular system
    33620000
  • 33621000Medicinal products for the blood and blood-forming organs33622000Medicinal products for the cardiovascular system

Similar active competitions

  • Region Nordjylland

    Engroshandel med medisinske og husholdningsvarer

    Produkt til hæmostase - Gelatinegranulat med thrombin - flydende

    Region Nordjylland har brug for et produkt til hæmostase (gelatinegranulat med thrombin - flydende) til en rammeaftale over 4 år med en maksimal totalværdi på 41 millioner DKK. Produktet skal primært anvendes ved operative indgreb til at forebygge, begrænse eller standse blødning i operationsfeltet som supplement til almindelige kirurgiske hæmostasemetoder. Levering skal ske til Region Nordjylland, Østjylland, Sydjylland, Vest- og Sydsjælland samt Københavns omegn, med Region Sjælland og Region Hovedstaden som option. Tilbud vil blive evalueret ud fra økonomi (40%), kvalitet og funktion (55%) samt emballage og miljø (5%). Janssen-Cilag A/S, Mediq Danmark A/S, Baxter A/S og UnoBak V-Tech ApS har lignende kontrakter i dag.

    Framework agreement
    Nov 18, 2026(11 days)
    DKK 41,000,000

  • Nemocnica Poprad, a.s.

    Antihemoragiká - Fibrinogenum humanum

    Nemocnica Poprad, a.s. potrebuje dodať a distribuovať antihemoragický liek s účinnou látkou ľudský fibrinogén do Prešovského kraja; maximálna celková hodnota zákazky je 56 911,55 EUR. Podrobné technické špecifikácie a podmienky dodania upravujú súťažné podklady a návrh rámcovej kúpnej zmluvy. Jediným kritériom výberu je najnižšia celková cena za požadované množstvo vrátane DPH (100 %).

    Competition
    Dec 8, 2026(31 days)
    €56,911

  • HOSPICES CIVILS DE LYON Etablissement support du GHT VAL RHÔNE CENTRE Direction des Achats

    Farmasøytisk engroshandel

    Fourniture de Médicaments Dérivés du Sang, recombinants et issus de Thérapie Génique.

    Fourniture de Médicaments Dérivés du Sang, recombinants et issus de Thérapie Génique.

    Dynamic purchasing system